– Protective effects on acute pancreatitis observed
– Indicative of potential in other acute-inflammatory-related conditions
ROCKVILLE, MD and SHENZHEN, CHINA, May 06, 2025—HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, announced today that it presented at Digestive Disease Week® (DDW) 2025, taking place from May 3-6, 2025 in San Diego. The presentation presents preclinical findings for rimtoregtide (HTD4010), a peptide derived from the Reg3α protein, in a model of acute pancreatitis in rats.
“The Protective Effects of Rimtoregtide (HTD4010) on Acute Pancreatitis in Rats”
(Presentation TU1416, Poster Presentation, May 6, 12:30-1:30 PM PDT)
About the Abstract: The purpose of this study was to test the potential protective effects of HTD4010 in sodium taurocholate-induced model of acute pancreatitis in rats. Treatment with HTD4010 resulted in significant protective effects in a sodium-taurocholate-induced acute pancreatitis rat model including significantly improved survival rates compared to the model control; decreased amylase and lipase levels; alleviation of multi-organ injury as evidenced by macroscopic observations during sacrifice; and alleviation of pancreatic damage as evidenced by histological evaluation. These findings provide evidence that HTD4010 may have a beneficial effect on acute pancreatitis and other acute-inflammatory-related conditions.
About Rimtoregtide
Rimtoregtide (HTD4010) is a clinical-stage compound in development for acute inflammatory-related indications including alcoholic hepatitis (AH). It is a peptide derived from the Reg3α protein with immunomodulatory, anti-inflammatory, and anti-apoptotic effects. HTD4010 has been evaluated in animal models of acute pancreatitis and acute liver failure, where protective effects were observed. A completed Phase 1 clinical trial of HTD4010 in healthy subjects demonstrated a favorable safety profile. AH is caused by chronic heavy alcohol abuse or a sudden, drastic increase in alcohol consumption. It is characterized by severe inflammation and, ultimately, liver failure and death. There is currently no approved treatment for AH and only a few drug candidates are in clinical development. The current standard of care focuses on symptom management, including abstinence, treating inflammation and providing nutrition.
About HighTide Therapeutics
HighTide Therapeutics, Inc. (Stock Code: 2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional, multi-targeted therapies with poly-indication potential across chronic liver and metabolic diseases with significant unmet medical needs. HighTide is currently developing several clinical assets and associated global intellectual property rights, and advancing multiple mid-to-late-stage clinical trials including therapies for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes mellitus (T2DM), severe hypertriglyceridemia (SHTG) and primary sclerosing cholangitis (PSC). Berberine ursodeoxycholate (HTD1801), HighTide’s lead drug candidate, received Fast Track designation from the United States Food and Drug Administration for both MASH and PSC and Orphan Drug designation for PSC. HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project in China.
For more information, please visit www.hightidetx.com
Contact: pr@hightidetx.com